Background The lethality of hepatocellular carcinoma (HCC) stems rom its propensity for distant metastasis and resistance to therapeutic agents, together making it a leading contributor to cancer mortality worldwide. Within the HCC microenvironment, cancer-associated fibroblasts (CAFs) promote tumor progression in part through secreted factors, among which stromal cell-derived factor-1 (SDF-1/CXCL12) signals through its receptor CXCR4, a chemokine receptor that is overexpressed in HCC and correlates with poor prognosis [13,17,38]. Aberrant histone deacetylation is a key epigenetic regulator of HCC progression [20,21,23]. Here, we aimed to investigate the role of fibroblast-derived SDF-1 in modulating histone acetylation through CXCR4 signaling and its impact on HCC cell behavior. Methods The role of SDF-1 in HCC was investigated using an indirect co-culture model of HepG2 cells and LX2 hepatic stellate cells. SDF-1, CXCR4, HDAC2, and HDAC6 were manipulated by knockdown and overexpression; cell behavior was assessed by Transwell migration, wound healing, CCK-8 viability, and flow cytometric apoptosis assays, and histone acetylation was examined by Western blotting, with the HDAC inhibitor vorinostat used as a comparator. Public single-cell RNA-sequencing data (GSE149614) were used to assess fibroblast SDF-1 enrichment. Results Our results showed that SDF-1 derived from LX2 cells promoted HepG2 cell migration and proliferation. SDF-1 treatment increased the expression of the mesenchymal markers Snail and Vimentin together with the epithelial marker E-cadherin, a pattern consistent with partial or hybrid epithelial-mesenchymal plasticity rather than a canonical EMT [19,39]. SDF-1 also suppressed global histone acetylation of H2A, H2B, H3, and H4 by upregulating the histone deacetylases HDAC2 and HDAC6. SDF-1 therefore suppresses histone acetylation and enhances HCC cell migration, proliferation, and epithelial-mesenchymal plasticity. Conclusion This study indicates that fibroblast-derived SDF-1 modulates histone acetylation and regulates HCC cell migration, proliferation, and epithelial-mesenchymal plasticity. Whether the SDF-1/CXCR4 axis is a viable therapeutic target remains to be tested in vivo. Trial registration Not applicable.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: